Advanced search
Publication Cover
Acta Cardiologica Volume 66, 2011 - Issue 1
Submit an article Journal homepage
5
Views
8
CrossRef citations to date
0
Altmetric
Articles

Natriuretic peptides and collagen biomarkers in patients with medical treatment for hypertension

Paavo UusimaaInstitute of Clinical Medicine, Department of Internal Medicine, University of Oulu, Oulu, Finland.;Oulu Deaconess Institute, Oulu, Finland.Correspondence[email protected]
, MD,
Sini PeuhkurinenInstitute of Clinical Medicine, Department of Internal Medicine, University of Oulu, Oulu, Finland.
, MD,
Antti YlitaloOulu Deaconess Institute, Oulu, Finland.;Satakunta Central Hospital, Pori, Finland.
, MD,
Olli VuolteenahoInstitute of Biomedicine, Department of Physiology and Biocenter Oulu, University of Oulu, Oulu, Finland.
, MD,
Juha RisteliInstitute of Diagnostics, Department of Clinical Chemistry, University of Oulu, Oulu, Finland.
, MD &
Keijo PeuhkurinenOulu Deaconess Institute, Oulu, Finland.;Department of Internal Medicine, University of Kuopio, Kuopio, Finland.
Pages 21-27 | Received 15 Jun 2010, Accepted 28 Sep 2010, Published online: 23 May 2017

References

  • Kjeldsen SE, Dahl8f B, Devereux RB, Julius 5, Aurup P. Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen 0, Lindholm LH, Nieminen MS, Omvik P. Oparil 5, Snapinn 5, Wedell H for the LIFE Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. JAMA 2002; 288:1491–8.
  • Klingbeil AU, Schneider M, Martus P. Messerli FH, Schmieder RE.A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41–6.
  • Kohno M, Norio T, Yokokawa K, Yasunari K, Ikeda M, Minami M, Kurihara N, Takeda T. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: Changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am J Med 1995; 98: 257–65.
  • Talwar 5, Siebenhofer A, Williams B, Ng L. Influence of hypertension, left ventricularhypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP. Heart 2000; 83: 278–82.
  • Rubattu 5, Sciarretta 5, Ciavarella GM, Venturelli V. De Paolis P, Tocci G, De Biase L, Ferrucci A, Volpe M. Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. J Hypertension 2007; 25:833–9.
  • Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol 2003; 92: 1434–8.
  • Uusimaa P, Tokola H, Ylitalo A, Vuolteenaho 0, Ruskoaho H, Risteli J, Ylitalo A, Peuhkurinen K on behalf of the Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Plasma B-type natriuretic peptide reflects left ventricularhypertrophy and diastolic function in hypertension. Int J Cardiol 2004; 97: 251–6.
  • Diez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 1995; 91: 1450–6.
  • Uusimaa P. Risteli J, Niemel6 M, Lumme J, Ik6heimo M, Jounela A, Peuhkurinen K. Collagen scar formation after acute myocardial infarction. Relationships to infarct size, left ventricular function and coronary artery patency. Circulation 1997; 96: 2565–72.
  • Lopez B, Querejeta R, Varo N, Laviades C, Querjeta R, Dietz J. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104:286–91.
  • Poulter NR, Wedel H, Dahl8f B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, östergren J, Pocock S for the ASCOT investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366:907–13.
  • Uusimaa P, Tokola H, Ruskoaho H, Vuolteenaho 0, Risteli J, Ylitalo A, Peuhkurinen K on behalf of the ASCOT investigators. Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure: design of the study and patient characteristics. J Hum Hypertension 2001; 15(suppl 1): 519-522.
  • Miiller-Brunotte R, Kahan T, Malmqvist K, Ring M, Edner M.Tissue velocity echocardiography shows early improvement in diastolic function with erbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results from the Swedish I rbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA). Am J Hypertens 2006; 19:927–36.
  • Solomon SC, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourcière Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JMO, Thomas JD, Zile MR, Aurigemma GP for the Valsartan in Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007; 369: 2079–87.
  • Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt BR. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertension 2005; 23:1083–90.
  • Ohbayashi Y, TsutamotoT, Sakaguchi T, Tanaka T, Kanamori T, Yokohama H, Sichiri G, Hukai D, Okabayashi T, Ozawa T, Ishii C, Tsutsui T, Ohno K, Ohnishi M, Wada A. Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine. J Cardiovasc Pharmacol 2003; 42(Suppl 1): S71–574.
  • Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt RN-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and leftventricular hypertrophy: a LIFE study. J Hypertension 2004; 22:1597–1604.
  • Olsen MH, Christensen MK, Wachtell K, Tuxen C, Fossum E, Bang LE, Wiinberg N, Devereux RB, Kjeldsen SE, Hilderandt P. Dige-Petersen H, Rokkedal J, Ibsen H. Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy. J Hum Hypertension 2005; 19: 301–7.
  • Ciulla MM, Paliotti R, Esposito A, DiezJ, Lopez P. Dahl& B, Nicholls G, Smith RD, Gilles L, Magrini F, Zanchetti A. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis. Results of a randomized trial. Circulation 2004; 110:552–7.
  • Nishikawa N, Masayama T, Yamamoto K, Skata Y, ManoT, Miwa T, Sugawara M, Hon i M. Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. J Am Coll Cardiol 2001; 38:1539–45.
  • Rajzer M, Klocek M, Kaweck-Jaszcz K. Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertension 2003; 16:439–44.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.